Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 17 November
This article announces a Form 4 filing for United Therapeutics Corporation concerning Martine A. Rothblatt, who serves as Director, Chairperson, and CEO. The filing pertains to activities on November 17. Form 4 filings are used to report changes in beneficial ownership of securities by company insiders.
Form 4 UNITED THERAPEUTICS Corp For: Nov 17 Filed by: ROTHBLATT MARTINE A
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), filed a Form 4 detailing stock transactions on November 17, 2026. The filing indicates the exercise of 9,500 stock options at $117.76 per share and the subsequent sale of 9,500 common stock shares in multiple transactions at weighted average prices ranging from $576.1626 to $584.2163. These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.
A family trust exercised options at $117.76 per share and sold United Therapeutics (UTHR) shares the same day.
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), reported that a family trust she influences exercised 9,500 options at $117.76 per share on November 17, 2026, and simultaneously sold 9,500 common shares across 11 lots at weighted-average prices around $576 to $586. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan established in November 2025. Following these transactions, the trust holds 5,410 options and over 628,049 common shares, while Rothblatt directly holds 40,513 shares.
United Therapeutics CEO Rothblatt sells $5.58M in stock
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (NASDAQ:UTHR), sold approximately $5.58 million in common stock on November 16, 2026, as part of a pre-arranged trading plan. Concurrently, Ms. Rothblatt acquired 9,500 shares through stock options exercise for $1.11 million, increasing her beneficial ownership to 668,728 shares. The company reported record Q3 revenue but missed EPS forecasts, while analysts maintained positive ratings and raised price targets.
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 16 November
This article reports a Form 4 filing for United Therapeutics Corporation, detailing that Martine A. Rothblatt, in her capacity as Director, Chairperson, and CEO, made a transaction on November 16. Form 4 filings are used to declare changes in beneficial ownership of securities by company insiders. The article indicates the filing was published on November 17, 2026, at 22:20.
A CEO trust exercises 9,500 options at $117.76, then sells United Therapeutics (UTHR) shares.
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp. (UTHR), reported that a family trust exercised 9,500 stock options at $117.76 per share on November 16, 2026, then sold 9,500 common shares in multiple trades under a pre-arranged Rule 10b5-1 trading plan. The transactions generated an approximate pre-tax spread of $4.46 million from gross sale proceeds of $5.58 million and exercise costs of $1.12 million. Following the transactions, the trust holds 14,910 stock options and over 628,000 common shares.
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 13 November
This article reports on a Form 4 filing for United Therapeutics Corporation, detailing transactions by Martine A. Rothblatt, who serves as Director, Chairperson, and CEO. The filing pertains to activity on November 13th. The article is a brief announcement of this SEC filing.
United Therapeutics CEO Rothblatt sells $5.6 million in shares By Investing.com
Martine A. Rothblatt, CEO of United Therapeutics Corp, sold 9,500 shares for over $5.6 million on November 13, 2026, as part of a pre-arranged trading plan, coinciding with the stock nearing its 52-week high. The sale followed the exercise of stock options acquired at a significantly lower price. Despite the stock appearing overvalued by some analyses, the company recently reported record third-quarter revenue, leading several analysts to raise price targets.
UTHR: Record TYVASO momentum and multiple 2027 pipeline catalysts define the outlook
United Therapeutics Corporation (UTHR) reported Q3 revenue of $833M, driven by record TYVASO revenue and October referrals. The company anticipates several key catalysts in 2027, including a ralinepag review, a planned SMI filing, PPF trial readouts, and preparations for an IPF launch. This outlook is based on the UBS Global Biopharma Conference 2026 Audio Transcript.
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 15 September
This article reports on a Form 4 filing for United Therapeutics Corporation, specifically detailing transactions made by Martine A. Rothblatt, who serves as Director, Chairperson, and CEO. The filing is for September 15th, indicating a disclosure of changes in her beneficial ownership of company securities. The article reiterates this information multiple times.
United Therapeutics CEO Martine Rothblatt sells $4.77M in stock By Investing.com
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp. (NASDAQ:UTHR), sold approximately $4.77 million worth of company stock on September 15, 2026, after exercising stock options. These transactions were carried out under a pre-arranged 10b5-1 trading plan. The company recently reported record third-quarter revenue, though its stock is considered overvalued by InvestingPro analysis.
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 15 September
This article reports on a Form 4 filing for United Therapeutics Corporation, detailing that Martine A. Rothblatt, who serves as Director, Chairperson, and CEO, made a transaction on September 15. Form 4 filings are used to declare changes in beneficial ownership of securities by a company's officers, directors, and principal stockholders. The article provides the basic announcement without further details on the nature of the transaction.
Liquidia retains PAH drug YUTREPIA rights post-settlement, limiting PH-ILD market but securing revenue.
Liquidia Corporation settled with United Therapeutics, securing the rights to market YUTREPIA for pulmonary arterial hypertension (PAH) but conceding some commercial potential in pulmonary hypertension associated with interstitial lung disease (PH-ILD). Despite this limitation, the company can still generate revenue from existing PH-ILD patients and PAH patients. Liquidia also has another drug, L606, in development for PH-ILD, suggesting positive long-term prospects.
Liquidia: Yutrepia's PAH Franchise Has Room To Grow
Liquidia Corporation maintains the right to market YUTREPIA for Pulmonary Arterial Hypertension (PAH) following a settlement with United Therapeutics, though its potential in PH-ILD is limited. Despite this, YUTREPIA continues to generate revenue from existing patients and those with PAH. Liquidia also has L606, offering another potential entry into the PH-ILD market, leading to a bullish outlook on the company's long-term prospects.
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 11 November
This article reports on a Form 4 filing for United Therapeutics Corporation, detailing an insider transaction involving Martine A. Rothblatt, who serves as Director, Chairperson, and CEO. The filing pertains to activity on November 11. The article simply notes the filing without providing further details on the transaction itself.
Here's How Much $100 Invested In United Therapeutics 15 Years Ago Would Be Worth Today
United Therapeutics (NASDAQ: UTHR) has significantly outperformed the market over the past 15 years, achieving an average annual return of 19.5%. An investment of $100 in UTHR stock 15 years ago would now be worth $1,448.51. This illustrates the substantial impact of compounded returns on cash growth over time.
A CEO trust exercises options, then sells United Therapeutics (UTHR) shares under a trading plan.
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), conducted an exercise-and-sale of 9,500 stock options at $117.76 per share, and subsequently sold the resulting 9,500 common shares across 14 transactions on November 10, 2026. This activity was executed under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Post-transaction holdings include various options and common shares held directly and indirectly through family trusts.
After exercising 9,500 options, the CEO’s family trust sells United Therapeutics (UTHR) shares.
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), had a family trust exercise 9,500 stock options at $117.76 per share on November 11, 2026. Subsequently, the trust sold 9,500 common shares in multiple transactions, with weighted-average prices ranging from $584.2008 to $598.6281 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025.
LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales
Liquidia Corporation (LQDA) reported strong third-quarter 2026 earnings, surpassing analyst estimates for both earnings per share and revenue, driven by robust sales of its lead drug, Yutrepia. Despite a significant one-time litigation settlement charge, the company's Yutrepia sales maintained momentum, and its cash position is expected to support future investments and payment obligations. Liquidia also continues to advance its clinical pipeline, including studies for Yutrepia in various indications and the development of L606 for pulmonary hypertension.
United Therapeutics CEO sells $4.76M in stock after option exercise By Investing.com
Martine A. Rothblatt, CEO of United Therapeutics Corp, sold 9,500 shares for $4.76 million after exercising stock options. These transactions were conducted under a pre-arranged trading plan. Despite the sale, the stock has seen a 29% increase over the past year, trading near its 52-week high, although InvestingPro analysis suggests it may be overvalued.
Form 144 UNITED THERAPEUTICS CORPORATION For: 11 November By Investing.com
This article from Investing.com announces a Form 144 filing by UNITED THERAPEUTICS CORPORATION for November 11th. Form 144 is a notice of the intent to sell restricted securities. The article provides the title and links to further details on the Investing.com platform.
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 16 September
This article reports on a Form 4 filing for United Therapeutics Corporation, specifically detailing transactions by Martine A. Rothblatt, who serves as Director, Chairperson, and CEO. The filing is dated for September 16. Form 4 documents are mandatory filings with the SEC for company insiders to report their stock transactions.
A CEO family trust sold 7,886 United Therapeutics (UTHR) shares and exercised 9,500 options.
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), reported that a family trust in which she shares investment power exercised 9,500 stock options and sold 7,886 common shares on November 9, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following these transactions, the trust still holds 62,410 stock options and a significant number of common shares.
Under a pre-arranged plan, United Therapeutics (UTHR) CEO family trusts sold 1,614 shares.
Family trusts associated with United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt sold a total of 1,614 common shares on November 9, 2026. These sales were executed under a pre-arranged 10b5-1 trading plan adopted on November 7, 2025, with weighted-average prices ranging from $583.8007 to $585.6258 per share. The plan is set to continue until the earlier of the exercise of 1,734,410 stock options or December 31, 2026.
After exercising options, United Therapeutics (UTHR) director sells 1,210 shares at $580 each.
United Therapeutics Corp. (UTHR) director Christopher Patusky exercised stock options for 1,210 common shares at $132.30 each and then sold those same shares for $580 each on November 9, 2026. This transaction resulted in approximately $542,000 in pre-tax spread from gross sale proceeds of $702,000 and an exercise cost of $160,000. After the transaction, Patusky held 3,000 stock options directly and 2,140 common shares directly, with an additional 1,100 common shares held indirectly by a trust.
Rochester now has a xenotransplant facility in its backyard. Experts say this field is primed for progress
United Therapeutics Corp. has opened a $110 million sterile facility in Stewartville, Minnesota, dedicated to raising genetically modified pigs for xenotransplantation. This facility aims to address the critical shortage of human organs for transplant by providing compatible pig organs. Scientists highlight advances in gene editing and anti-rejection drugs as key drivers of progress in the field, with pigs being the preferred animal due to their scalability and lifespan.
After exercising options at $117.76 a share, United Therapeutics (UTHR) CEO trust sells 9,500 shares.
Martine A. Rothblatt's family trust, associated with United Therapeutics (UTHR) Chairperson & CEO, exercised options for 9,500 common shares at $117.76 per share on November 6, 2026, and subsequently sold all 9,500 shares in nine transactions on the same day. This activity was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan is set to continue until the earlier of the exercise of 1,734,410 stock options (expiring March 15, 2027) or December 31, 2026.
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 6 November
This article reports on a Form 4 filing for United Therapeutics Corporation, detailing an insider transaction by Martine A. Rothblatt, who serves as Director, Chairperson, and CEO. The filing specifically pertains to activity that occurred on November 6. The article itself was published on November 9, 2026.
H.C. Wainwright resumed coverage on United Therapeutics with a new price target
H.C. Wainwright has resumed coverage on United Therapeutics (UTHR) with a "Buy" rating and set a new price target of $660.00. This analyst action was highlighted by Quantisnow, noting that previous UTHR headlines have resulted in varied stock movements, with a median change of 1.3%. The report also includes historical stock performance data after specific corporate announcements.
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
United Therapeutics Corporation (Nasdaq: UTHR) announced that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update at two upcoming investor conferences in London: the UBS Global Biopharma Conference on November 16, 2026, and the Jefferies Global Healthcare Conference on November 17, 2026. Both sessions will be accessible via live webcast on the company's website. The company, a public benefit corporation, focuses on treating rare diseases and pioneering alternatives for transplantable organs.
Martine Rothblatt, United Therapeutics CEO, sells $4.3M in shares By Investing.com
Martine A. Rothblatt, CEO of United Therapeutics Corp (NASDAQ:UTHR), sold 8,160 shares worth approximately $4.33 million and exercised options for 9,500 shares valued at $1.12 million, all under a pre-arranged trading plan. The company maintains strong fundamentals, including an 86% gross profit margin, despite InvestingPro suggesting the stock may be overvalued. This follows United Therapeutics reporting record Q3 revenue, exceeding analyst estimates, driven by strong demand for Tyvaso.
Martine Rothblatt, United Therapeutics CEO, sells $4.3M in shares
Martine Rothblatt, CEO of United Therapeutics Corp (NASDAQ:UTHR), sold 8,160 shares worth approximately $4.33 million and exercised options for 9,500 shares valued at $1.12 million, all under a pre-arranged 10b5-1 trading plan. The company maintains strong fundamentals, including an 86% gross profit margin and more cash than debt, despite InvestingPro suggesting the shares might be overvalued. United Therapeutics also reported record Q3 revenue of $832.5 million, driven by strong Tyvaso demand, though EPS missed estimates.
Nine planned sales by CEO-linked trusts at United Therapeutics (UTHR) total 1,960 shares.
Family trusts associated with Martine A. Rothblatt, Chairperson and CEO of United Therapeutics (UTHR), sold a total of 1,960 common shares across nine transactions on November 5, 2026. These sales were executed as part of a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following these transactions, Martine A. Rothblatt directly holds 40,513 common shares.
Family trusts sell 1,723 United Therapeutics (UTHR) shares under a pre-arranged plan.
Family trusts linked to Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), sold 1,723 common shares on November 4, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales occurred at weighted-average prices ranging from $610.2928 to $613.1350 per share. This trading plan is scheduled to continue until the earlier of exercising 1,734,410 stock options or December 31, 2026.
The 5 most interesting analyst questions from United Therapeutics’s Q3 2026 earnings call
United Therapeutics (UTHR) reported Q3 2026 revenue that exceeded expectations, driven by strong demand for Tyvaso, but operating margins and GAAP profit declined. The article highlights five key analyst questions from the earnings call, covering topics such as the impact of regulatory label changes, sales force expansion, regulatory risks for new therapies, and the development path for future drugs. Management provided insights into these issues, with a focus on upcoming catalysts like regulatory filings and the effectiveness of sales strategies.
Family trusts sell 7,777 United Therapeutics (UTHR) shares and exercise 9,500 options.
Martine A. Rothblatt's family trusts, associated with United Therapeutics (UTHR), executed a pre-arranged Rule 10b5-1 trading plan on November 4, 2026. This involved exercising 9,500 stock options at $117.76 per share and subsequently selling 7,777 common shares in multiple trades, with weighted-average sale prices reaching up to $609.0929. The plan, adopted in November 2025, is set to continue until either 1,734,410 stock options are exercised or December 31, 2026.
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 4 November
This article reports on a Form 4 filing for United Therapeutics Corporation, detailing a transaction involving Martine A. Rothblatt, who serves as a Director, Chairperson, and CEO. The filing specifically pertains to activity that occurred on November 4th. This type of filing is a mandatory report by company insiders regarding changes in their ownership of company stock.
Billionaire Martine Rothblatt's firm posts record $833m Q3
Martine Rothblatt's United Therapeutics reported record third-quarter revenue of $832.5 million, exceeding analyst forecasts, driven by strong sales of Tyvaso DPI. Despite a dip in net income due to increased research spending, the company is poised for significant growth with new therapies and strategic acquisitions. United Therapeutics also settled a royalty deal with Pfizer and approved a new $2 billion share buyback program.
United Therapeutics Pays $525 Million to Eliminate Pfizer Royalties on Ralinepag
United Therapeutics (NASDAQ: UTHR) has made an upfront payment of $525 million to Pfizer to remove future royalty obligations on ralinepag, an experimental treatment for pulmonary arterial hypertension (PAH). This agreement allows United Therapeutics to retain more revenue if ralinepag receives regulatory approval and is commercialized, and it underscores the company's confidence in the drug's market potential. While future royalties are eliminated, United Therapeutics remains responsible for contingent regulatory milestone payments totaling $400 million.
United Therapeutics buys out Pfizer royalties linked to lung disease therapy
United Therapeutics (UTHR) announced the acquisition of Pfizer's (PFE) royalty interest in ralinepag, an experimental lung disease therapy, for an upfront payment of $525 million. This deal eliminates future royalty obligations to Pfizer for ralinepag, which is currently under FDA review. The announcement came alongside UTHR's Q3 2026 results, which showed revenue growth but a decline in net income due to increased R&D costs.
United Therapeutics (UTHR) Misses Q3 EPS by 50c, Beats on Revenue
United Therapeutics (UTHR) reported its Q3 earnings, missing analyst estimates for EPS by $0.50 with a reported $5.71 compared to an estimated $6.21. However, the company surpassed revenue expectations, bringing in $832.5 million against a consensus estimate of $785.44 million.
United Therapeutics (NASDAQ:UTHR) beats Q3 2026 sales expectations, stock soars
United Therapeutics (NASDAQ:UTHR) reported Q3 2026 results that exceeded revenue expectations, with sales up 4.1% year-on-year to $832.5 million, causing its stock to surge 5.9%. While revenue growth was strong, the company's GAAP profit of $5.71 per share missed analyst estimates by 5.5%, and its adjusted operating margin decreased. Despite the EPS miss, the market reacted positively to the significant revenue beat.
United Therapeutics Corporation Reports Third Quarter 2026 Financial Results
United Therapeutics Corporation reported a four percent year-over-year increase in total revenues to $832.5 million for the third quarter of 2026, driven by strong growth in Tyvaso DPI sales. Despite increased revenues, net income decreased by 24% to $258.6 million, primarily due to higher research and development expenses related to asset acquisitions and organ alternative projects, as well as a decrease in interest income. The company also announced a new $2.0 billion share repurchase program approved in October 2026.
CEO trusts sell 9,500 United Therapeutics (UTHR) shares after an option exercise at $117.76.
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, through family trusts, exercised options for 9,500 common shares at an exercise price of $117.76 on November 2, 2026. The resulting shares were subsequently sold in seven transactions under a pre-arranged Rule 10b5-1 trading plan. After these transactions, the family trust reported holding 109,910 options.
Form 144 United Therapeutics Corporation For: 3 November By Investing.com
This article announces that United Therapeutics Corporation filed a Form 144 for November 3rd. A Form 144 indicates an intent to sell restricted securities, providing transparency on potential insider transactions. The article provides the filing date and mentions the company's stock symbol (UTHR).
United Therapeutics (UTHR) to report earnings tomorrow: here is what to expect
United Therapeutics (NASDAQ:UTHR) is set to announce its earnings results before market hours this Wednesday. The market anticipates a 2.1% year-on-year revenue decline, despite the company beating revenue expectations last quarter. Investor sentiment in the therapeutics segment is positive, with United Therapeutics' shares up 11.2% over the last month.
United Therapeutics (UTHR) to report earnings tomorrow: here is what to expect
United Therapeutics (UTHR) is scheduled to announce earnings results on Wednesday before market hours. The market anticipates a 2.1% year-on-year revenue decline for this quarter, a reversal from the previous year's increase, despite the company beating revenue and EPS expectations last quarter. Investor sentiment in the therapeutics segment is positive, with United Therapeutics' shares up 11.2% over the last month.
Under a preset trading plan, United Therapeutics (UTHR) CEO sells 9,500 shares.
United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at $117.76 per share and subsequently sold 9,500 common shares from family trusts on October 30, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. The plan is set to continue until either 1,734,410 stock options are exercised or December 31, 2026, whichever occurs first, with a reported post-transaction option position of 119,410 stock options.
Form 144 UNITED THERAPEUTICS Corp Filed by: ROTHBLATT MARTINE A
Martine A. Rothblatt, an officer of United Therapeutics Corporation, filed a Form 144 to report the proposed sale of 119,410 shares of common stock with an aggregate market value of $71,493,155.20, acquired through the exercise of stock options on November 2, 2026. The filing also details numerous 10b5-1 sales made by Rothblatt and/or the Martine Rothblatt Property Management Trust during the past three months, with total gross proceeds exceeding $200 million. This sale is scheduled to occur on November 2, 2026, via Morgan Stanley Smith Barney LLC on NASDAQ.
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 17 September
This article reports on a Form 4 filing for United Therapeutics Corporation, detailing an insider transaction by Martine A. Rothblatt, who serves as Director, Chairperson, and CEO. The filing pertains to activity on September 17. The article itself provides minimal detail beyond the announcement of the filing.